$PRVL News
Last published 3y ago
- 3y agoPRVLSafety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS - NCT05737121ClinicalTrials.govSum of bladder pain intensity differences from baseline to 12 hours post-dose (SPID-12), Sum of bladder pain intensity differences from baseline to 6, 10, and 24 hours post-dose (SPID-6, SPID-10, and SPID-24, respectively), Change in bladder pain from baseline to 1, 4, 8, 12, and 24 hours post-dose, (and 3 more...)
- 5y agoLLYPRVLLilly Completes Acquisition of Prevail TherapeuticsPR NewswireEli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The...
- 5y agoAAPLLLYPRVLBMY+7Stocks making the biggest moves midday: Apple, Baidu, Chewy and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 5y agoLLYPRVLBMYWPP-GB+10Stocks making the biggest moves in the premarket: Prevail Therapeutics, Moderna, Apple, Pinterest & moreCNBCThe stocks making the biggest moves in premarket trading include Prevail Therapeutics, Moderna, Apple, Pinterest, and more.
- 5y agoLLYPRVLLilly Announces Agreement to Acquire Prevail TherapeuticsPR NewswireEli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail...
- 5y agoPRVLPrevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN MutationsGlobeNewswireNEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 5y agoPRVLPrevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal DementiaGlobeNewswireNEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 5y agoPRVLPrevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001GlobeNewswireNEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 5y agoPRVLPrevail Therapeutics Reports Third Quarter 2020 Financial Results and Business HighlightsGlobeNewswirePatient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Phase 1/2 PROVIDE Trial of PR001 for Type 2 Gaucher Disease and Phase 1/2 PROCLAIM Trial of...
- 6y agoPRVLPrevail Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireNEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEOGlobeNewswireNEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher DiseaseGlobeNewswireNEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireNEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech SummitGlobeNewswireNEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics Announces Appointment of William H. Carson, M.D., to Board of DirectorsGlobeNewswireNEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireNEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics Inc.'s (PRVL) CEO Asa Abeliovich on Q2 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
- 6y agoPRVLPrevail Therapeutics Reports Second Quarter 2020 Financial Results and Business HighlightsGlobeNewswirePreliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients Company Modifies Protocol for PROPEL...
- 6y agoPRVLPrevail Therapeutics to Present at 2020 Wedbush PacGrow Healthcare ConferenceGlobeNewswireNEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial ResultsGlobeNewswireNEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR006GlobeNewswireNEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer’s Association International ConferenceGlobeNewswirePreclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases Company Provides Overview of Planned Phase 1/2 PR006...
- 6y agoPRVLPrevail Therapeutics Appoints Kira Schwartz, J.D., as General CounselGlobeNewswireNEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics to Present at The Jefferies Virtual Global Healthcare ConferenceGlobeNewswireNEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
- 6y agoPRVLPrevail Therapeutics to Participate in Fireside Chat at Chardan 4th Annual Genetic Medicines Manufacturing SummitGlobeNewswireCEO, CTO to Discuss Company’s Manufacturing and CMC Strategy and Overall Industry Trends NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company...
- 6y agoPRVLPrevail Therapeutics to Highlight Multiple CNS-Focused Gene Therapy Programs at 2020 American Society of Gene & Cell Therapy Annual MeetingGlobeNewswirePreclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases Company Provides Design Overview for Planned Phase 1/2...
- 6y agoPRVLPrevail Therapeutics Reports Full Year 2019 Financial Results and Business HighlightsGlobeNewswireDosing Initiated in PROPEL Phase 1/2 Trial of PR001 for Treatment of Parkinson’s Disease with GBA1 Mutations Preparations Underway to Initiate PROVIDE Phase 1/2 Trial of PR001 for Treatment of Type...
- 6y agoPRVLPrevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN MutationGlobeNewswireNEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutationsGlobeNewswireNEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN MutationGlobeNewswireNEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
- 6y agoPRVLPrevail Therapeutics to Present at Upcoming ConferencesGlobeNewswireNEW YORK, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
- 6y agoPRVLPrevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020GlobeNewswireNEW YORK, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
- 6y agoPRVLPrevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher DiseaseGlobeNewswireNEW YORK, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
- 7y agoPRVLPrevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business HighlightsGlobeNewswireOpened Enrollment of PROPEL Phase 1/2 Trial of PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations PR001 for Neuronopathic Gaucher Disease and PR006 for Frontotemporal Dementia with GRN...
- 7y agoPRVLPrevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative DiseasesGlobeNewswireStrategic collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs for patients with neurodegenerative diseases Companies to...
- 7y agoPRVLPrevail Therapeutics to Present at Upcoming October ConferencesGlobeNewswireNEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
- 7y agoPRVLPrevail Therapeutics Announces Addition to Russell 2000®, 3000® and Microcap® IndexesGlobeNewswireNEW YORK, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
- 7y agoPRVLPrevail Therapeutics Provides Program Update on PR001 in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher DiseaseGlobeNewswireNEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ: PRVL), a biotechnology company developing AAV-based gene therapies for patients with neurodegenerative disorders,...
- 7y agoPRVLPrevail Therapeutics Announces Pricing of Initial Public OfferingBusiness WireNEW YORK--(BUSINESS WIRE)--Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $17.00 per share. In addition, Prevail has granted the un ...